No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Jiangsu Nhwa Pharmaceutical Co., LTD operates as a global pharmaceutical entity, focusing on the research, production, and sale of treatments for the central nervous system, along with cardiovascular and cerebrovascular ailments. Its comprehensive product line includes therapeutics for anesthesia, psychiatry, and neurological disorders. Additionally, the company is a supplier of Active Pharmaceutical Ingredients (APIs), specifically for central nervous system, anesthetic, and sedative applications, among others. The firm was established in 1978 and is based in Xuzhou, China.
www.nhwa-group.comNo one on the platform currently holds 002262.SZ.
No tracked institution reports a position in 002262.SZ as of their last filing.
No one on the platform has traded 002262.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 14.0% | 20.6% | 22.6% | — | — | — |
| Rev. Growth % | 2.7% | 11.7% | ||||
| Profit Margin % | 18.1% | 20.0% | 17.3% | |||
| Free Cash Flow Margin % | 11.8% | 11.5% | 11.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $6.5B | +4.3% | $1.18 | $1.16–$1.20 | — | 2 |
| 2027 | $7.3B | +11.7% | $1.33 | $1.32–$1.34 | — | 2 |
| 2028 | $8.1B | +11.7% | $1.53 | $1.46–$1.57 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-17 | $0.37 | $0.42 | +13.5% |
| 2026-04-20 | $0.47 | $0.31 | -34.0% |
| 2026-04-17 | $0.21 | $-0.05 | -123.0% |
| 2025-10-24 | $0.42 | $0.40 | -4.8% |
| 2025-07-29 | $0.39 | $0.39 | +0.0% |
| 2025-04-18 | $0.31 | $0.30 | -3.2% |
| 2025-03-28 | $0.17 | $0.12 | -29.4% |
| 2024-10-25 | $0.41 | $0.39 | -4.9% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002262.SZJiangsu Nhwa Pharmaceutical Co., Ltd. | $21.59 | -0.28% | $21.9B | — |
| 000513.SZLivzon Pharmaceutical Group Inc. | $26.29 | -1.09% | $23.3B | — |
| 000963.SZHuadong Medicine Co., Ltd | $26.23 | +0.15% | $46.0B | — |
| 002223.SZJiangsu Yuyue Medical Equipment & Supply Co., Ltd. | $25.95 | -0.46% | $26.0B | — |
| 002294.SZShenzhen Salubris Pharmaceuticals Co., Ltd. |
| $29.67 |
| +0.24% |
| $33.1B |
| — |
| 002422.SZSichuan Kelun Pharmaceutical Co., Ltd. Class A | $40.41 | -0.59% | $64.3B | — |
| 002773.SZChengdu Kanghong Pharmaceutical Group Co., Ltd | $19.12 | -0.05% | $17.6B | — |
Source: Financial Modeling Prep · peers by sector/industry